Zenas BioPharma reported a net loss of $137.3 million for the nine months ended September 30, 2025, compared with a $104.4 million loss for the same period a year earlier. For the full year ended December 31, 2025, the company posted a net loss of $377.7 million, a sharp increase from the $157.0 million loss reported for 2024. Revenue for 2025 rose to $10.0 million, driven by a one‑time upfront license payment, up from $5.0 million in 2024.
The widening loss is largely attributable to a $171.7 million charge for acquired in‑process R&D, the largest single expense in the year. R&D spending climbed to $168.1 million in 2025, up from $139.1 million in 2024, reflecting higher clinical‑trial and manufacturing costs for the company’s lead candidates obexelimab and orelabrutinib. General and administrative expenses also increased, contributing to the overall loss. These expenses, combined with the one‑time AIPR&D charge, explain why the full‑year loss is more than double the prior year’s figure.
Cash and liquidity remain a key focus. The company’s cash balance was $301.6 million as of September 30, 2025, and rose to $360.5 million by December 31, 2025. Management indicated that the current runway extends into the fourth quarter of 2026, with potential extension into the first quarter of 2027 depending on future financing and milestone achievements. The company has secured a $250 million debt facility from Pharmakon Advisors and a royalty‑financing agreement with Royalty Pharma for up to $300 million, which are expected to support ongoing pipeline development.
CEO Lonnie Moulder emphasized progress in the company’s autoimmune disease pipeline and the strategic importance of the new financing. He noted that the cash position and financing arrangements provide a buffer, but also acknowledged substantial doubt about the company’s ability to continue as a going concern, underscoring the need for continued funding and milestone attainment.
Analyst expectations for the quarter were modest. For the third quarter of 2025, the diluted EPS was –$1.22, missing the consensus estimate of –$1.02, and revenue was $0, falling short of the $10.0 million estimate. The results highlight the company’s ongoing investment in research and development, which has yet to translate into revenue growth beyond the license payment.
Market reaction to the earnings was negative; the company’s stock closed down 4.49 % on the day of the release, reflecting investor concern over the large net loss, the significant AIPR&D charge, and the going‑concern warning. The market’s response underscores the sensitivity of investors to the company’s financial trajectory and the importance of future milestones and financing to restore confidence.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.